Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
NCT03775265Phase 3
Key facts
- Status
- Active, not recruiting
- Start
- Jun 2019
- Primary completion
- Jun 2027
- Countries
- 1
- Sponsor
- National Cancer Institute
- Modality
- Monoclonal Antibodies
- Drugs
- atezolizumab
- Conditions
- muscle-invasive bladder cancer (MIBC)
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Bladder intact event-free survival at 5 years. Started Jun 2019; status: active, not recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
Arm I (RT, chemotherapy)
Standard of care chemoradiotherapy
Arm II (RT, chemotherapy, atezolizumab)
Chemoradiotherapy + Atezolizumab
03
Who it enrols
Adults with T2-T4a N0M0 muscle invasive bladder cancer who have not received prior systemic chemotherapy or pelvic radiation, with adequate organ function and Zubrod PS <= 2.
04
Endpoints
Primary
Bladder intact event-free survival
Secondary
Overall survival
Modified bladder intact event-free survival
Biopsy response
Complete response duration
Progression-free survival
Metastasis-free survival
Cancer-specific survival
Quality of life
Beyond the preview
Go deeper on NCT03775265.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03775265.